BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 19062062)

  • 1. Efficient in vitro expansion of JC virus-specific CD8(+) T-cell responses by JCV peptide-stimulated dendritic cells from patients with progressive multifocal leukoencephalopathy.
    Marzocchetti A; Lima M; Tompkins T; Kavanagh DG; Gandhi RT; O'Neill DW; Bhardwaj N; Koralnik IJ
    Virology; 2009 Jan; 383(2):173-7. PubMed ID: 19062062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy.
    Du Pasquier RA; Kuroda MJ; Zheng Y; Jean-Jacques J; Letvin NL; Koralnik IJ
    Brain; 2004 Sep; 127(Pt 9):1970-8. PubMed ID: 15215217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequency and phenotype of JC virus-specific CD8+ T lymphocytes in the peripheral blood of patients with progressive multifocal leukoencephalopathy.
    Lima MA; Marzocchetti A; Autissier P; Tompkins T; Chen Y; Gordon J; Clifford DB; Gandhi RT; Venna N; Berger JR; Koralnik IJ
    J Virol; 2007 Apr; 81(7):3361-8. PubMed ID: 17229701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JC virus-specific cytotoxic T lymphocytes in individuals with progressive multifocal leukoencephalopathy.
    Koralnik IJ; Du Pasquier RA; Letvin NL
    J Virol; 2001 Apr; 75(7):3483-7. PubMed ID: 11238876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of prolonged survival in HLA-A2+ progressive multifocal leukoencephalopathy patients with a CTL response specific for a commonly recognized JC virus epitope.
    Koralnik IJ; Du Pasquier RA; Kuroda MJ; Schmitz JE; Dang X; Zheng Y; Lifton M; Letvin NL
    J Immunol; 2002 Jan; 168(1):499-504. PubMed ID: 11751998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy.
    Perkins MR; Ryschkewitsch C; Liebner JC; Monaco MC; Himelfarb D; Ireland S; Roque A; Edward HL; Jensen PN; Remington G; Abraham T; Abraham J; Greenberg B; Kaufman C; LaGanke C; Monson NL; Xu X; Frohman E; Major EO; Douek DC
    PLoS Pathog; 2012; 8(11):e1003014. PubMed ID: 23144619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JCV-specific cellular immune response correlates with a favorable clinical outcome in HIV-infected individuals with progressive multifocal leukoencephalopathy.
    Du Pasquier RA; Clark KW; Smith PS; Joseph JT; Mazullo JM; De Girolami U; Letvin NL; Koralnik IJ
    J Neurovirol; 2001 Aug; 7(4):318-22. PubMed ID: 11517410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JC virus-specific immune responses in human immunodeficiency virus type 1 patients with progressive multifocal leukoencephalopathy.
    Khanna N; Wolbers M; Mueller NJ; Garzoni C; Du Pasquier RA; Fux CA; Vernazza P; Bernasconi E; Viscidi R; Battegay M; Hirsch HH;
    J Virol; 2009 May; 83(9):4404-11. PubMed ID: 19211737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overview of the cellular immunity against JC virus in progressive multifocal leukoencephalopathy.
    Koralnik IJ
    J Neurovirol; 2002 Dec; 8 Suppl 2():59-65. PubMed ID: 12491153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Presence of JC virus-specific CTL in the cerebrospinal fluid of PML patients: rationale for immune-based therapeutic strategies.
    Du Pasquier RA; Autissier P; Zheng Y; Jean-Jacques J; Koralnik IJ
    AIDS; 2005 Dec; 19(18):2069-76. PubMed ID: 16284455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determinants of survival in progressive multifocal leukoencephalopathy.
    Marzocchetti A; Tompkins T; Clifford DB; Gandhi RT; Kesari S; Berger JR; Simpson DM; Prosperi M; De Luca A; Koralnik IJ
    Neurology; 2009 Nov; 73(19):1551-8. PubMed ID: 19901246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low frequency of cytotoxic T lymphocytes against the novel HLA-A*0201-restricted JC virus epitope VP1(p36) in patients with proven or possible progressive multifocal leukoencephalopathy.
    Du Pasquier RA; Kuroda MJ; Schmitz JE; Zheng Y; Martin K; Peyerl FW; Lifton M; Gorgone D; Autissier P; Letvin NL; Koralnik IJ
    J Virol; 2003 Nov; 77(22):11918-26. PubMed ID: 14581528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BKV and JCV large T antigen-specific CD8+ T cell response in HLA A*0201+ kidney transplant recipients with polyomavirus nephropathy and patients with progressive multifocal leukoencephalopathy.
    Chen Y; Trofe J; Gordon J; Autissier P; Woodle ES; Koralnik IJ
    J Clin Virol; 2008 Jun; 42(2):198-202. PubMed ID: 18295538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of CD4+ and CD8+ T-cell responses against JC virus in the outcome of patients with progressive multifocal leukoencephalopathy (PML) and PML with immune reconstitution inflammatory syndrome.
    Gheuens S; Bord E; Kesari S; Simpson DM; Gandhi RT; Clifford DB; Berger JR; Ngo L; Koralnik IJ
    J Virol; 2011 Jul; 85(14):7256-63. PubMed ID: 21543472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric immune receptors (CIRs) specific to JC virus for immunotherapy in progressive multifocal leukoencephalopathy (PML).
    Yang W; Beaudoin EL; Lu L; Du Pasquier RA; Kuroda MJ; Willemsen RA; Koralnik IJ; Junghans RP
    Int Immunol; 2007 Sep; 19(9):1083-93. PubMed ID: 17660502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased program cell death-1 expression on T lymphocytes of patients with progressive multifocal leukoencephalopathy.
    Tan CS; Bord E; Broge TA; Glotzbecker B; Mills H; Gheuens S; Rosenblatt J; Avigan D; Koralnik IJ
    J Acquir Immune Defic Syndr; 2012 Jul; 60(3):244-8. PubMed ID: 22549384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Critical role of JC virus-specific CD4 T-cell responses in preventing progressive multifocal leukoencephalopathy.
    Gasnault J; Kahraman M; de Goër de Herve MG; Durali D; Delfraissy JF; Taoufik Y
    AIDS; 2003 Jul; 17(10):1443-9. PubMed ID: 12824781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brief Report: Decreased JC Virus-Specific Antibody-Dependent Cellular Cytotoxicity in HIV-Seropositive PML Survivors.
    Tan CS; Ghofrani J; Geiger E; Koralnik IJ; Jost S
    J Acquir Immune Defic Syndr; 2019 Oct; 82(2):220-224. PubMed ID: 31513076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human polyomavirus JC reactivation and pathogenetic mechanisms of progressive multifocal leukoencephalopathy and cancer in the era of monoclonal antibody therapies.
    Bellizzi A; Nardis C; Anzivino E; Rodìo D; Fioriti D; Mischitelli M; Chiarini F; Pietropaolo V
    J Neurovirol; 2012 Feb; 18(1):1-11. PubMed ID: 22290500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of JC virus-specific cytotoxic T lymphocytes in healthy individuals.
    Du Pasquier RA; Schmitz JE; Jean-Jacques J; Zheng Y; Gordon J; Khalili K; Letvin NL; Koralnik IJ
    J Virol; 2004 Sep; 78(18):10206-10. PubMed ID: 15331755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.